Latest Breaking News On - Karin hellsvik - Page 2 : comparemela.com

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

First-in class BRM selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024 .

United kingdomUnited statesAdam silversteinPeter kelleherAdrian gottschalkKarin hellsvikGreg dearbornExchange commissionTherapeutics incFoghorn therapeutics incCompany annual report on formAmerican association for cancer researchCancer researchChief executive officerChief scientific officerFoghorn therapeutics

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2 2024

United kingdomUnited statesGreg dearbornPeter kelleherAdrian gottschalkKarin hellsvikAdam silversteinExchange commissionFoghorn therapeutics incCompany annual report on formTherapeutics incAmerican association for cancer researchCancer researchChief executive officerChief scientific officerFoghorn therapeutics

Foghorn Therapeutics Presents New Preclinical Data On Potential First-In-Class BRM Selective Inhibitor FHD-909 And Selective CBP And Selective EP300 D

Foghorn Therapeutics Presents New Preclinical Data On Potential First-In-Class BRM Selective Inhibitor FHD-909 And Selective CBP And Selective EP300 D
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesKarin hellsvikGreg dearbornAdam silversteinAdrian gottschalkPeter kelleherAmerican association for cancer researchCompany annual report on formExchange commissionFoghorn therapeutics incTherapeutics incCancer researchChief executive officerChief scientific officerFoghorn therapeutics

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesKarin hellsvikPeter kelleherGreg dearbornAdrian gottschalkAdam silversteinCompany annual report on formExchange commissionAmerican association for cancer researchTherapeutics incFoghorn therapeutics incCancer researchChief executive officerChief scientific officerFoghorn therapeutics

Foghorn Therapeutics to Participate in Needham s 23rd Annual Virtual Healthcare Conference -April 05, 2024 at 07:00 am EDT

Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class.

United kingdomKarin hellsvikPeter kelleherAdam silversteinAdrian gottschalkGreg dearbornFoghorn therapeutics incExchange commissionCompany annual report on formTherapeutics incAnnual needham virtual healthcareGene trafficChief executiveAnnual reportFoghorn therapeuticsLifesci advisors